TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015. The Corporation's unaudited Q1 2016 financial statements and MD&A are available on SEDAR.
Antibe is performing validation studies in an effort to gain a better understanding of why the higher doses of ATB-346 caused damage to liver cells in some subjects in the Phase 1 clinical trial. Two potential mechanisms are being investigated.
Help employers find you! Check out all the jobs and post your resume.
Antibe is performing validation studies in an effort to gain a better understanding of why the higher doses of ATB-346 caused damage to liver cells in some subjects in the Phase 1 clinical trial. Two potential mechanisms are being investigated.
Help employers find you! Check out all the jobs and post your resume.
